Wednesday, Sanofi released data from a Phase II study showing its investigational anti-CD40L antibody frexalimab met the trial’s primary endpoint and significantly lowered disease activity in patients with relapsing multiple sclerosis.
Sanofi is the latest company to do some spring cleaning of its pipeline. Thursday morning, the pharma announced it will discontinue two acquired programs in its Q1 update.
The FDA has placed a partial clinical hold on a Phase I study of Foghorn Therapeutics’ investigational protein degrader FHD-609 after a patient developed a grade 4 QTc prolongation event, the company announced Monday.
Blueprint Medicines Corp. said on Friday the U.S. drug regulator had put on partial hold an early-stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.
CytoDyn withdrew its pending Biologics License Application for the monoclonal antibody in HIV Friday, citing concerns involving the contract research organization managing its trials.
On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.